Good Promotion Practices Alliance
Plenty of attention being paid to pharmaceutical marketing fraud and abuse cases in blogs and in the general media. But there hasn't been much attention paid to good compliance solutions or best practices. That's the mission of the Good Promotion Practices Alliance (GPP), which is co-sponsored by Reprints Desk and Prolifiq Software.
Certain Physician-Drug Industry Relationships Have Declined Dramatically
The authors of a physician survey published in the November 8, 2010, issue of Archives of Internal Medicine conclude 'given that 83.8% of physicians have PIRs, it is clear that industry still has substantial financial links with the nation's physicians. These findings support the ongoing need for a national system of disclosure of PIRs [Physician-Drug Industry Relationships].' Such a system is part of the Physician Sunshine Law, which is scheduled to go into effect in 2012 with public disclosure of payments scheduled to begin September, 2013.
GSK’s U.S. Sales Reps “Europeanized”: No Longer Rewarded for Ability to Push Prescriptions
An anonymous poster to CafePharma described what the
Pharma Marketing News Vol. 10, No. 5: 10 MARCH 2011
Welcome to Volume 10, Issue #5 (10 MARCH 2011) of Pharma Marketing News.
Politics Vs. Science in the Plan B Decision
Sebelius focused on the fact that Teva's study did not contain data for all ages for which this product would be available for use. According to Tina Raine-Bennett, MD, MPH, of the Women's Health Research Institute at Kaiser Permanente Northern California, a principal investigator of the University of California-San Francisco study, it is unreasonable and virtually impossible to study the use of emergency contraception in 11- and 12-year-olds, because only a small fraction of them will have had sex by that age.
The Big C in the Big Apple
HepC.tv is featuring the video 'Man-on-the-Street: New Yorkers' Reactions to the Big Yellow C.' Is it effective? How do we know?
A New Estimate of Drug Development Cost
Economic Experts Disagree Wildly on How Much It Costs to Bring a New Drug to Market. How is it that the Tufts estimate is at least 14 TIMES the London School of Economics and Political Science (LSEPS) estimate? 'Make no mistake,' said Tufts. 'Tufts CSDD will vigorously defend the scholarship, integrity, and validity of all its published research studies.'
The British Pharmaceutical Industry Issues Social Media Guidance for Adverse Event Reporting
Once again the Brits have beaten the US in issuing useful guidelines for social media use by the pharmaceutical industry! As I reported back in April, 2011, the Prescription Medicines Code of Practice Authority (PMCPA), which oversees the self-regulatory code of the Association of the British Pharmaceutical Industry (ABPI), published
Four Useful Lessons Pharma Can Learn from the Pfizer Facebook Hack
Pfizer's US corporate Facebook page was hacked by some 'Kiddies.' What should the industry learn from this experience?
In Memory of Steve Jobs Will Novartis Sales Reps Really Embrace iPads?
David Epstein, head of Novartis Pharmaceuticals, said eighty percent of his company's sales reps will give up their PCs for iPads in 2012. Will they do it?
